Patents by Inventor Dhruv Kam Sethi

Dhruv Kam Sethi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20230026259
    Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities. In particular, the present application is directed to fusion proteins comprising a fragment of human human carbonic anhydrase 2 and a chimeric antigen receptor (CAR). The activity of the destabilizing domain can be regulated by externally administered agents.
    Type: Application
    Filed: March 6, 2020
    Publication date: January 26, 2023
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Vipin SURI, Celeste RICHARDSON, Brian DOLINSKI, Abhishek KULKARNI, Mara Christine Inniss, Dexue SUN, Elizabeth Jane WEISMAN, Grace Y. Olinger, Scott Francis HELLER, Jennifer Leah GORI, Michelle Lynn OLS, Kutlu Goksu ELPEK, Tucker Read EZELL, Michael SCHEBESTA, Michelle Lois FLEURY, Dhruv Kam SETHI
  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
    Publication number: 20220380459
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.
    Type: Application
    Filed: May 3, 2022
    Publication date: December 1, 2022
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Dhruv Kam Sethi, William Haney, Bianka Prinz, Bradley M. Lunde, Ronnie Wei, Daniel Fallon, Steven O'Neil
  • CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
    Publication number: 20220332780
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (EL15) payloads, as well as compositions and methods of use thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: October 20, 2022
    Inventors: Kutlu Goksu ELPEK, Dhruv Kam SETHI, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER
  • CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20220267398
    Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 25, 2022
    Inventors: Michelle Lynn OLS, Vipin SURI, Dexue SUN, Dhruv Kam SETHI, Michael SCHEBESTA, Michelle Lois FLEURY, Kutlu Goksu ELPEK
  • CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20220175781
    Abstract: The present disclosure provides regulatable biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Michael SCHEBESTA, Michelle Lois FLEURY, Kutlu Goksu ELPEK, Elizabeth Jane WEISMAN, Vipin SURI, Dexue SUN, Dan Jun LI, Steven Mark SHAMAH, Michael Joseph BRISKIN, Celeste RICHARDSON, Tariq A. KASSUM, Michelle Lynn OLS, Brian DOLINSKI, Mara Christine INNISS, Emily BRIDEAU, Jennifer Leah GORI, Dhruv Kam SETHI
  • MEMBRANE BOUND IL12 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20220056092
    Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 24, 2022
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Michelle Lynn OLS, Vipin SURI, Dexue SUN, Dan Jun LI, Dhruv Kam SETHI, Abhishek KULKARNI, Benjamin J. PRIMACK, James STORER
  • PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
    Publication number: 20210261668
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 26, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Dhruv Kam Sethi, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • CA2 compositions and methods for tunable regulation
    Patent number: 11058725
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: July 13, 2021
    Assignee: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
    Publication number: 20210101976
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.
    Type: Application
    Filed: February 20, 2019
    Publication date: April 8, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Dhruv Kam Sethi, William Haney, Bianka Prinz, Bradley M. Lunde
  • ANTIBODY VARIABLE DOMAINS TARGETING CD33, AND USE THEREOF
    Publication number: 20200376034
    Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen binding site targeting CD33 (Siglec-3) on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Dhruv Kam Sethi, William Haney, Bianka Prinz
  • PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
    Publication number: 20200216544
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 9, 2020
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Dhruv Kam Sethi, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz